A 15-year-old girl has short stature and the hand finding shown . Labs show ↓Ca²⁺, ↑PO₄³⁻, ↑PTH. What is the most likely diagnosis? https://t.co/afPUeaqfZT

If you missed this pattern, you missed an autoimmune classic What’s it? https://t.co/zO48zPCkqP

#ACR25 Abstract 1526 “Guidance for #Steroid Tapering in Systemic Lupus Erythematosus” 101 international experts reached Delphi consensus on CS tapering strategies in #SLE. 🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement. https://t.co/GRlUz3Y3EP

🍼 “Stop breastfeeding if on methotrexate” — that’s what we’ve always heard. But here’s the news 👇 📊 Latest EULAR lactation: Methotrexate = LoE 4 / C ➡️ May be considered in breastfeeding if no safer alternative exists. 💡Not first-line, not forbidden — just evidence-limited. https://t.co/IJEpZYMaFV

@Janetbirdope’s #ACR25 pearls remind us: Order ANA only when clinical suspicion exists Never repeat a positive ANA ENA only if ANA+ ❌ Ignore dsDNA if ANA– (except anti-Ro52) Stop serial dsDNA/C3/C4 if stable Smart lab use saves patients anxiety and systems money. #SLE https://t.co/Mu3EefcIx0

Really great visual summaries by Athena Chin, Sam Whittle and colleagues: Recs for the Use DMARDs in Pregnancy and Reproductive Health for Pts w Rheumatic Disease: A Scoping Review - Oct 2025 - Arthritis Care & Research #Rheumatology #MedEdu https://t.co/zRJcTESJWN 🇦🇺 https://t.co/OYZVtLEYr7

Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: https://t.co/56eOK86lmn ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w https://t.co/cR4RVfWPlI

Early Peripheral SpA: Is it okay to stop treatment sometimes? Dr. Richard Conway reports on abstract 0568 "Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial," presented at #ACR25 https://t.co/FtI2o90v9O https://t.co/jUAEDZhDW5

Is Low Disease Activity Low Enough? Drs. Jonathan Kay and Joel Kremer discuss abstract 0449, "Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life". #ACR25 https://t.co/kI8qOYjVL4

GLP-1 Receptor Agonists: Impacts Beyond Metabolism? Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our https://t.co/Xl6M3xSvlq